Despite this, serum CA-125 levels cannot accurately discriminate benign from malignant ovarian lesions in premenopausal women (11), and CA-125 testing has low sensitivity in early disease stages (12), and does not provide detailed molecular information about the tumor. The gene discussed is MUC16; the disease is neoplasm.